When any large pharmaceutical company (& i am not implying Prima is one, my refereance is to the BIG pharma) changes CEO's it is one of the most interesting periods for the company to see how they play their cards - programs are chopped left right & center while new programs & core areas of focus are determined.
Matthew Lehman shouldn't be underestimated with his ability to bring forward signifcant change in the company that can be seen today with the first chops I'd say fairly likely there will be developments to fill the gaps in the near future, he's already highlighted he sees value in aquiring technology, products or even companies to compliment existing assets aswell as further strategic alliances.
Interesting few months ahead as the cards are dealt & ML builds his rep as CEO.
When any large pharmaceutical company (& i am not implying Prima...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.010(2.78%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 36.0¢ | $563.7K | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 386559 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 261422 | 13 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |